February 2022

In a new study, Du, et al., have identified a neutralising monoclonal antibody in humans, 87G7, against SARS-CoV-2 which has shown widespread neutralisation and immunisation efficacy against SARS-CoV-2 VOCs...

In recent study published in Science, Wymant, et al., reported the presence of a subtype-B variant of HIV-1 with high virulence that has been spreading through the Netherlands during recent times. Does this highlight the importance of monitoring viral variants?

Researchers today are still trying to understand how the immune system's natural killer (NK) cells identify SARS-CoV-2 infected cells. In a recent paper, Hammer, et al., have reported that NK cells respond to a certain peptide on the surface of infected cells...

In a new study published in Nature Communications, Launonen, et al., have identified and described the mechanism of how ovarian cancer hides from the body's immune system. These findings have produced novel insights for the development of new targeted therapeutics against the devastating disease.

In a new study, Harris, et al., investigated the potential health impact and cost-effectiveness of the M72/AS01E vaccine in two high burden TB countries: India and South Africa

A recent paper by Foix, et al., has reported on the potential of existing strains of SARS-CoV-2, and future variants to escape the immune system's cytotoxic T cell response.

In a recent paper, Ziyang, et al., have produced novel insights into and further developed an HIV vaccine through the use of a unique trimer in order to develop Tier-2 neutralizing antibodies...

In a recent study, researchers have demonstrated that the SARS-CoV-2 receptor-binding domain (RBD)-based, sortase A-conjugated nanoparticle (RBD-scNP) vaccine induces neutralizing antibodies (NAbs) in non-human primates (NHPs) against all eight variants of SARS-CoV-2.

In a recent study published in Science, Melani, et al., have reported on a several families of proteins in the body that may be used as a tool to predict which patients may be susceptible to rejection of a new organ transplant. This has the potential to aid clinicians in making informed decisions with regards to treatments.

For decades, researchers have suspected that patients infected with a common virus, Epstein-Barr (EVB), might be more likely to develop multiple sclerosis. Now, a team led by Harvard University researchers reports what some say is the most compelling evidence yet of a strong link between these two diseases.